Please login to the form below

Not currently logged in
Email:
Password:

MRSA

This page shows the latest MRSA news and features for those working in and with pharma, biotech and healthcare.

Motif Bio preps US filing after antibiotic clears phase III

Motif Bio preps US filing after antibiotic clears phase III

resistance to other antibiotics, including ‘superbugs’ such as methicillin resistant Staphylococcus aureus (MRSA).

Latest news

  • CHMP backs AZ's 'superbug' antibiotic product CHMP backs AZ's 'superbug' antibiotic product

    In 2011 AZ launched novel cephalosporin Zinforo (ceftaroline fosamil), the first drug in the class to be approved with data showing it could tackle the superbug methicillin-resistant Staphylococcus aureus (MRSA).

  • Pfizer takes MRSA vaccine into phase IIb trial Pfizer takes MRSA vaccine into phase IIb trial

    Trial will involve patients undergoing elective spinal fusion surgery.  . Pfizer has started enrolling patients into a mid-stage trial of its candidate vaccine for 'superbug' methicillin-resistant Staphylococcus aureus (MRSA). ... The company is trying

  • Basilea’s novel antibiotic reaches UK market Basilea’s novel antibiotic reaches UK market

    It is a broad-spectrum antibiotic and can be used to treat infections caused both Gram- positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas species. ... Treatment failure rates in pneumonia,

  • Cubist gets green light from FDA for new antibiotic Sivextro Cubist gets green light from FDA for new antibiotic Sivextro

    Sivextro is in the oxazolidinone class of antibiotics has been approved to treat ABSSSIs caused by certain Gram-positive bacteria, including 'superbug' methicillin-resistant Staphylococcus aureus (MRSA), and is available in ... Until the approval of

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    In November 2013, it won priority review from the US FDA for acute bacterial SSSIs caused by susceptible Gram-positive bacteria (including MRSA). ... Dalbavancin has an improved dosing regimen and increased potency versus vancomycin against Gram-positive

More from news
Approximately 4 fully matching, plus 76 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics